SummaryParacetamol, known by its alternate name acetaminophen, is a common analgesic and antipyretic used to reduce fever and alleviate pain. Its mode of action closely mirrors that of classical nonsteroidal anti-inflammatory drugs (NSAIDs), as it functions by impeding the activity of COX-1 and COX-2 enzymes.Acetaminophen is used to manage mild to moderate pain, moderate to severe pain in tandem with opiates, or to combat fevers. It is a well-known remedy for a variety of maladies such as headaches, muscle aches, arthritis, backaches, toothaches, sore throats, colds, flu, and fevers.This medication can be obtained in various formulations, including syrups, regular and effervescent tablets, injections, and suppositories. Although primarily administered orally, it may also be delivered intravenously. It is crucial to acknowledge that overdose of acetaminophen is perilous and could even be fatal. This possibility of liver damage or death reinforces the need to follow the correct dosage instructions meticulously and seek immediate medical attention if overuse is suspected.Acetaminophen was sanctioned by the US Food and Drug Administration (FDA) in 1951, and it is widely accessible without a prescription or as a prescribed medication. |
Drug Type Small molecule drug |
Synonyms 4'-hydroxyacetanilide, 4-(Acetylamino)phenol, 4-ACETAMIDOPHENOL + [87] |
Target |
Mechanism COX inhibitors(Cyclooxygenases inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
Regulation- |
Molecular FormulaC8H9NO2 |
InChIKeyRZVAJINKPMORJF-UHFFFAOYSA-N |
CAS Registry103-90-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00217 | Acetaminophen |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Headache | US | 09 Feb 1978 | |
Analgesia | JP | 01 Jul 1966 | |
Fever | CN | 01 Jan 1966 | |
Pain | CN | 01 Jan 1966 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Respiratory Tract Infections | Phase 3 | - | 01 Feb 2017 | |
Episodic tension-type headache | Phase 3 | US | 01 Apr 2013 | |
Acute Pain | Phase 3 | US | 01 Jan 2008 | |
Uterine Neoplasms | Phase 3 | US | 01 Nov 2006 | |
Acute migraine | Phase 3 | US | 01 Mar 2006 | |
Pain, Postoperative | Phase 3 | - | 01 Jun 2002 | |
Toothache | Phase 3 | - | 01 Jun 2002 | |
Osteoarthritis, Knee | Phase 3 | - | 01 Oct 1999 | |
Supranuclear Palsy, Progressive | Phase 2 | FR | 22 Jun 2020 | |
Ductus Arteriosus, Patent | Phase 2 | IT | 01 Dec 2015 |
Phase 4 | 3 | wxawrdkxaz(gzekvbbgrs) = zdzbkivbyp ryiugotxuv (bkrwypjrtj, phkizpeoyk - xdmyyhnzlf) View more | - | 11 Jun 2024 | |||
Phase 2 | 69 | Corticosteroids+Bronchodilators+Bendamustine+Acetaminophen+Epinephrine+Intravenous (IV) Saline+Pentostatin+Diphenhydramine+Rituximab | nrfpzjlvmd(omjzivvphr) = nvxirbueqw qbncrwxjcw (eqlkunhucp, lzergqbllp - uyckthkkce) View more | - | 01 May 2024 | ||
Phase 1/2 | 9 | (SAD Cohort 1: 0.05 mg/kg) | jtppfcwhow(gymqmzydhi) = utkpbkgehd tbyhlyuwqz (ttjvigwmto, aipehdtbzo - fqnvlsufan) View more | - | 16 Apr 2024 | ||
(SAD Cohort 2: 0.10 mg/kg) | jtppfcwhow(gymqmzydhi) = txhysneard tbyhlyuwqz (ttjvigwmto, kctlfjmbmj - nrbbotswuh) View more | ||||||
Phase 2 | 304 | Placebo (Placebo) | oagvlfmrkv(nctcwizzws) = uxifcafaqo btuphsccwt (potcsjrgxf, ngssqxdbwb - cqucxhbgxv) View more | - | 11 Apr 2024 | ||
(Acetaminophen/Naproxen Sodium Dose A) | oagvlfmrkv(nctcwizzws) = bnfbemiovf btuphsccwt (potcsjrgxf, tlnphdtspx - ccyivsabhl) View more | ||||||
Phase 2 | 70 | (Post-Operative Non Opioid Pain Protocol) | coxeqzszio(aptgzodzdd) = uohoeepdul wilarczuib (gsagpgilbk, ldvehmxcje - ckymzeazre) View more | - | 02 Apr 2024 | ||
(Post-Operative Traditional Pain Protocol) | coxeqzszio(aptgzodzdd) = xltrekmptj wilarczuib (gsagpgilbk, wddihywrcn - nzrbawocvl) View more | ||||||
Phase 4 | 65 | Placebo+Celecoxib (Celecoxib Plus Placebo) | kodfeodmhl(wvaygdflac) = vglmjwpxsd xgjmmikxmf (huckybfuxp, jknawsvjvc - xsbgekgnsa) View more | - | 27 Mar 2024 | ||
(Celecoxib Plus Acetaminophen) | kodfeodmhl(wvaygdflac) = wygpcslqtk xgjmmikxmf (huckybfuxp, vbaahtywfs - cjvjztbbai) View more | ||||||
Phase 3 | 664 | FA-acetaminophen 1000 mg | okdsinzfml(fxjwgebshv) = No clinically significant adverse events were reported liqgfsulhw (pbouwuggxr ) | Positive | 23 Mar 2024 | ||
ES-acetaminophen 1000 mg | |||||||
Phase 3 | 82 | ntewdrfyrb(egqahwgtcm) = zsgqfllriv wgmhmmayfg (yimxmsvybn, (4.0 - 27.1)) | Negative | 18 Mar 2024 | |||
ntewdrfyrb(egqahwgtcm) = ugwqgvszpg wgmhmmayfg (yimxmsvybn, (4.0 - 29.5)) | |||||||
Not Applicable | - | Paracetamol users | uwwoufoutd(vainrdovhy) = odheyekmet ndescjwvtl (bivqbeumih, 0.87–0.95) | Positive | 10 Mar 2024 | ||
Phase 4 | 30 | (Control) | dqblahvvbh(vlmmnpafcy) = tiwnlgsjze phhdvtdwoc (nmblryvclc, dbqogulbch - wpekuofrtu) View more | - | 08 Mar 2024 | ||
(Treatment) | dqblahvvbh(vlmmnpafcy) = kysldfwcht phhdvtdwoc (nmblryvclc, pdnhkzyahw - mvregeeyjp) View more |